Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.53 |
| ▸ | HTR1A | P08908 | 4/20 | 0.53 |
| ▸ | HTR2A | P28223 | 4/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513130 | 0.89 | DRD2 (0.66) | DRD2HTR1AHTR2AHTR2CADRA1A | |
| Hydrochloric Acid SCHEMBL2702236 | 0.85 | HTR2A (0.54) | DRD2HTR1AHTR2AHTR2CADRA1A | |
| SCHEMBL293387 | 0.82 | DRD2 (0.53) | DRD2HTR1AHTR2AHTR2CADRA1A | |
| Hydrochloric Acid SCHEMBL4294507 | 0.82 | HTR2A (0.53) | DRD2HTR1AHTR2AHTR2CADRA1A | |
| SCHEMBL12062552 | 0.81 | DRD2 (0.53) | DRD2HTR1AHTR2AHTR2CADRA1A | |
| SCHEMBL294686 | 0.80 | HTR2A (0.53) | DRD2HTR1AHTR2AHTR2CADRA1A | |
| SCHEMBL294926 | 0.80 | HTR2A (0.53) | DRD2HTR1AHTR2A | |
| SCHEMBL294062 | 0.80 | HTR2A (0.53) | DRD2HTR1AHTR2A | |
| SCHEMBL1244053 | 0.80 | DRD2 (0.50) | DRD2HTR1AHTR2AHTR2CADRA1A | |
| SCHEMBL293244 | 0.80 | DRD2 (0.68) | DRD2HTR1AHTR2AHTR2CADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919907-B9 | HETEROCYCLIC COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-01-18 | — | — | EP | claimed |
| US-8071600-B2 | Derivatives of 4-piperazin-1-yl-4-benzo[B]thiophene suitable for the treatment of CNS disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-06 | — | — | US | claimed |
| EP-1919907-B1 | HETEROCYCLIC COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2011-02-23 | — | — | EP | claimed |
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-10-22 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264404-A1 | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | GRIN2C, GRIN2B, PMP22 | DRD2 139/4885HTR1A 29/4885HTR2A 92/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.